Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

AMLX

Amylyx Pharmaceuticals Inc

Dec 01 • 04:00PM ET

14.22

Dollar change +0.06
Percentage change 0.42	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.02	Insider Own	26.20%	Shs Outstand	66.51M	Perf Week	7.97%
Market Cap	959.99M	Forward P/E	6.55	EPS next Y	2.17	Insider Trans	-0.03%	Shs Float	49.76M	Perf Month	-16.84%
Income	1.84M	PEG	-	EPS next Q	0.28	Inst Own	84.57%	Short Float / Ratio	14.20% / 4.62	Perf Quarter	-34.83%
Sales	294.22M	P/S	3.26	EPS this Y	128.32%	Inst Trans	32.88%	Short Interest	7.07M	Perf Half Y	-43.53%
Book/sh	6.20	P/B	2.29	EPS next Y	126.04%	ROA	0.57%	Target Price	39.40	Perf Year	-62.94%
Cash/sh	5.26	P/C	2.70	EPS next 5Y	-	ROE	0.65%	52W Range	11.82 - 41.93	Perf YTD	-61.52%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	0.44%	52W High	-66.09%	Beta	-0.81
Dividend %	-	Quick Ratio	8.81	Sales past 5Y	2529.81%	Gross Margin	93.25%	52W Low	20.30%	ATR	0.88
Employees	262	Current Ratio	9.52	Sales Q/Q	29666.09%	Oper. Margin	-2.63%	RSI (14)	48.16	Volatility	5.52% 6.34%
Optionable	Yes	Debt/Eq	0.01	EPS Q/Q	132.62%	Profit Margin	0.62%	Rel Volume	0.59	Prev Close	14.16
Shortable	Yes	LT Debt/Eq	0.01	Earnings	Nov 09 BMO	Payout	-	Avg Volume	1.53M	Price	14.22
Recom	1.00	SMA20	0.47%	SMA50	-11.90%	SMA200	-39.89%	Volume	906,783	Change	0.42%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-24-23	Upgrade	Goldman	Neutral → Buy	$45 → $49
Mar-31-23	Initiated	Mizuho	Buy	$52
Jan-05-23	Initiated	BofA Securities	Buy	$50
May-25-22	Initiated	Citigroup	Buy	$21
Apr-01-22	Downgrade	Goldman	Buy → Neutral	$36 → $10

Nov-29-23 05:15PM	Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.19%
Nov-28-23 07:00AM	Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer (Business Wire)
Nov-27-23 09:00AM	RELYVRIO and AMX0114 Data to be Presented at 34th International Symposium on ALS/MND (Business Wire)
Nov-21-23 09:00AM	Amylyx Pharmaceuticals to Participate at the 6th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-12-23 11:59AM	Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q3 2023 Earnings Call Transcript (Insider Monkey)
12:26AM	Loading…
Nov-10-23 12:26AM	Q3 2023 Amylyx Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-09-23 05:04PM	Amylyx Crashes 32% On A Quarterly Report That Doesn't Bode Well For 2024 (Investor's Business Daily) -31.89%
12:12PM	Amylyx Crashes 27% As New ALS Drug Faces A Barrage Of Troubles (Investor's Business Daily)
08:05AM	Amylyx Pharmaceuticals Inc (AMLX) Reports Strong Q3 2023 Earnings with Significant Revenue Growth (GuruFocus.com)
07:00AM	Amylyx Pharmaceuticals Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-04-23 12:16PM	5 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds (Insider Monkey)
Nov-02-23 10:00AM	Amylyx Pharmaceuticals, Inc. (AMLX) Earnings Expected to Grow: What to Know Ahead of Q3 Release (Zacks) +5.38%
09:00AM	Amylyx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 9, 2023 (Business Wire)
Oct-19-23 09:00AM	Amylyx Pharmaceuticals to Present Clinical Trial Design of ORION, a Phase 3 Global Study of AMX0035 in Progressive Supranuclear Palsy (PSP), at the Neuro2023 PSP and CBD International Research Symposium (Business Wire)
Oct-18-23 08:30AM	Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More (Zacks)
08:26AM	Loading…
Oct-13-23 08:26AM	UPDATE 1-EU regulator declines to recommend Amylyx' ALS drug (Reuters)
07:55AM	EU regulator declines to recommend Amylyx' ALS therapy (Reuters)
07:45AM	Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination Process (Business Wire)
Oct-11-23 08:07AM	PTC Therapeutics (PTCT) Moves 5.3% Higher: Will This Strength Last? (Zacks)
Oct-10-23 09:45AM	2 Incredible Growth Stocks Near 52-Week Lows to Buy Now (Motley Fool)
09:12AM	Amylyx Pharmaceuticals Announces Publication of Survival Analysis Comparing CENTAUR to Historical Clinical Trial Control (Business Wire)
Oct-05-23 05:26PM	Amylyx Pharmaceuticals Provides Update on Accès Compassionnel for AMX0035 in France (Business Wire)
Oct-02-23 09:00AM	RELYVRIO and AMX0114 Data to be Presented at 22nd Annual Northeast ALS Consortium (NEALS) Meeting (Business Wire)
Sep-29-23 12:43PM	25 Biggest Stocks with Negative Beta (Insider Monkey)
02:54AM	14 Best Depressed Stocks To Buy Now (Insider Monkey)
Sep-20-23 09:02AM	Marinus Pharmaceuticals (MRNS) Soars 19.9%: Is Further Upside Left in the Stock? (Zacks)
Sep-05-23 09:00AM	Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire) -5.41%
Aug-28-23 11:53PM	3 Up-and-Coming Biotech Stocks to Put on Your Must-Buy List (InvestorPlace)
Aug-14-23 05:38AM	Amylyx's new ALS drug has turned a profit for six months straight (American City Business Journals)
Aug-13-23 08:26AM	Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q2 2023 Earnings Call Transcript (Insider Monkey)
08:47AM	Loading…
Aug-11-23 08:47AM	Q2 2023 Amylyx Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-10-23 05:15PM	Amylyx Pharmaceuticals, Inc. (AMLX) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
04:01PM	Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results (Business Wire)
Aug-03-23 04:05PM	Amylyx Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 10, 2023 (Business Wire)
Jul-28-23 12:56PM	3 Biotech Stocks to Buy Before Drug Trials End (InvestorPlace)
09:19AM	Goldman Sachs Predicts up to 120% Rally for These 2 Stocks Heres Why They Have Solid Upside (TipRanks)
Jul-24-23 12:17PM	Why Shares of Amylyx Pharmaceuticals Were Up Monday (Motley Fool)
Jul-19-23 05:00AM	Zacks.com featured highlights Carnival, Amylyx Pharmaceuticals and Alkami Technology (Zacks)
Jul-12-23 09:00AM	Amylyx Pharmaceuticals to Host Virtual Webcast on AMX0035 Progressive Supranuclear Palsy (PSP) Program (Business Wire)
Jun-27-23 10:57AM	Analysts Are Cutting Price Targets of These 10 Stocks (Insider Monkey)
Jun-26-23 10:36AM	Amylyx (AMLX) Down on Negative CHMP Opinion for ALS candidate (Zacks)
Jun-23-23 11:27AM	EMA's Advisory Panel Gives Thumbs Down To Amylyx Pharma's Amyotrophic Lateral Sclerosis Treatment (Benzinga) -6.94%
08:14AM	Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union (Business Wire)
Jun-15-23 09:00AM	Amylyx Pharmaceuticals Completes Negotiation Process and Signs Letter of Intent with the pCPA for ALBRIOZA for the Treatment of ALS (Business Wire)
Jun-13-23 11:15AM	Better Growth Stock: Amylyx Pharmaceuticals or Viking Therapeutics? (Motley Fool)
Jun-12-23 06:53AM	Companies Like Amylyx Pharmaceuticals (NASDAQ:AMLX) Can Afford To Invest In Growth (Simply Wall St.)
Jun-06-23 09:00AM	Amylyx Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference (Business Wire)
May-30-23 08:14AM	Amylyx says European regulator 'trending toward' negative opinion on ALS drug (Reuters)
08:00AM	Amylyx Pharmaceuticals Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS in the European Union (Business Wire)
May-16-23 11:29AM	Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2023 Earnings Call Transcript (Insider Monkey)
06:06AM	New Forecasts: Here's What Analysts Think The Future Holds For Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) (Simply Wall St.)
May-14-23 04:00PM	2 Supercharged Growth Stocks to Buy Right Now (Motley Fool)
08:06AM	Amylyx Pharmaceuticals, Inc. Just Reported A Surprise Profit, And Analysts Lifted Their Estimates (Simply Wall St.)
May-12-23 04:18PM	These Stocks Are Moving the Most Today: Tesla, First Solar, News Corp, Icahn Enterprises, Twilio, and More (Barrons.com)
04:07PM	Amylyx Unexpectedly Hits Breakeven With Breakneck Speed But Shares Dip (Investor's Business Daily)
08:16AM	Q1 2023 Amylyx Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
May-11-23 05:25PM	Amylyx Pharmaceuticals, Inc. (AMLX) Q1 Earnings and Revenues Surpass Estimates (Zacks)
04:42PM	Amylyx Blows Past Sales Expectations, Reports Unexpected Profit Shares Rocket (Investor's Business Daily)
04:01PM	Amylyx Pharmaceuticals Reports First Quarter 2023 Financial Results (Business Wire)
May-05-23 09:00AM	Amylyx Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023 (Business Wire)
Apr-20-23 09:00AM	Amylyx Pharmaceuticals Appoints Masako Nakamura to General Manager and Head of International Markets - Asia Pacific and Latin America (Business Wire)
Apr-17-23 02:24PM	Loss-Making Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Set To Breakeven (Simply Wall St.)
Apr-14-23 01:50PM	Amylyx (AMLX) Doses First Patient in Wolfram Syndrome Study (Zacks)
Apr-13-23 09:00AM	Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome (Business Wire)
Apr-11-23 09:00AM	Amylyx Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference (Business Wire)
Apr-09-23 01:19PM	7 Biotech Stocks to Buy for 100% Returns (InvestorPlace)
Apr-07-23 06:40PM	Tillys, American Public Education Stock See Action From Activist Investors (Barrons.com)
Apr-03-23 06:48AM	Daily Vickers Top Buyers & Sellers for 04/03/2023 (Argus Research)
Mar-30-23 06:36AM	Daily Vickers Top Buyers & Sellers for 03/30/2023 (Argus Research) -5.07%
Mar-24-23 06:42AM	Daily Vickers Top Buyers & Sellers for 03/24/2023 (Argus Research)
Mar-18-23 08:11AM	Party Time: Brokers Just Made Major Increases To Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Earnings Forecasts (Simply Wall St.)
Mar-17-23 06:47AM	Daily Vickers Top Buyers & Sellers for 03/17/2023 (Argus Research) -5.58%
Mar-15-23 07:07AM	Amylyx Pharmaceuticals (NASDAQ:AMLX) shareholders are still up 49% over 1 year despite pulling back 5.5% in the past week (Simply Wall St.)
Mar-14-23 04:02PM	Amylyx, A Top 5% Biotech Stock, Just Scored A Huge Win In ALS Treatment (Investor's Business Daily) +9.40%
12:31PM	Why Amylyx Pharmaceuticals Stock Is Bolting Higher Today (Motley Fool)
11:19AM	Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q4 2022 Earnings Call Transcript (Insider Monkey)
06:30AM	Q4 2022 Amylyx Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-13-23 04:03PM	Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Mar-08-23 09:00AM	Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Mar-07-23 07:00AM	Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023 (Business Wire)
Feb-27-23 06:50AM	Daily Vickers Top Buyers & Sellers for 02/27/2023 (Argus Research)
Feb-07-23 09:00AM	Amylyx Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference (Business Wire)
Feb-02-23 09:00AM	Amylyx Pharmaceuticals Announces Completion of Enrollment in Global Phase 3 PHOENIX Trial of AMX0035 in ALS (Business Wire) -6.07%
Jan-17-23 02:00AM	Amylyx Pharmaceuticals Announces Exclusive AMX0035 Distribution Agreement with Israel-Based Neopharm (Business Wire)
Nov-30-22 09:11AM	We're Not Very Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate (Simply Wall St.)
Nov-22-22 09:00AM	Amylyx Pharmaceuticals to Participate in the Evercore ISI 5th Annual HealthCONx Conference (Business Wire) +6.79%
Nov-16-22 11:00AM	Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm (Investor's Business Daily)
Nov-10-22 04:01PM	Amylyx Pharmaceuticals Reports Third Quarter 2022 Financial Results (Business Wire)
11:13AM	Checking on Amylyx Pharmaceuticals Ahead of Earnings (TheStreet.com)
Nov-07-22 10:42AM	Breakeven On The Horizon For Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) (Simply Wall St.)
Nov-03-22 04:05PM	Amylyx Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 10, 2022 (Business Wire)
Oct-24-22 10:13AM	10 Best Pharma Stocks To Buy Now (Insider Monkey)
Oct-16-22 09:48AM	Private equity firms are Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) biggest owners and were rewarded after market cap rose by US$170m last week (Simply Wall St.)
Oct-11-22 04:01PM	Amylyx Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (Business Wire)
Oct-10-22 04:48PM	Why a $158,000 Drug With Unclear Benefits Hurts Whole Health System (The Wall Street Journal) +5.24%
Oct-06-22 10:30PM	Amylyx Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock (Business Wire) +10.25%
Oct-05-22 03:42PM	Ice Bucket Challenge Beneficiary Throws Cold Water On Investors (TheStreet.com)
Oct-04-22 06:03PM	Top stocks trending after hours: Twitter, Amylyx Pharmaceuticals, AutoZone, AirBNB (Yahoo Finance)
05:03PM	Stocks moving after hours: Twitter, Amylyx Pharmaceuticals, AutoZone, Airbnb (Yahoo Finance Video)
04:23PM	Amylyx Pharmaceuticals Announces Launch of Public Offering (Business Wire)

Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in the provision of disease-modifying solutions for neurodegenerative diseases. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cohen Joshua B	Co-Chief Executive Officer	Nov 16	Option Exercise	1.57	63,694	100,000	2,906,311	Nov 20 08:20 PM
FRATES JAMES M	Chief Financial Officer	Aug 23	Option Exercise	6.88	18,165	124,975	106,341	Aug 24 04:15 PM
Mazzariello Gina	Chief Legal Officer	Aug 15	Sale	20.88	6,164	128,686	49,083	Aug 17 04:35 PM
Olinger Margaret	Chief Commercial Officer	Jul 12	Option Exercise	0.37	20,000	7,400	251,108	Jul 14 04:20 PM
FRATES JAMES M	Chief Financial Officer	May 16	Option Exercise	6.88	32,500	223,600	88,176	May 18 08:54 PM
FRATES JAMES M	Chief Financial Officer	May 16	Sale	26.94	32,500	875,451	55,676	May 18 08:54 PM
Yeramian Patrick D	Chief Medical Officer	May 15	Option Exercise	5.68	11,965	67,991	220,382	May 17 04:58 PM
Yeramian Patrick D	Chief Medical Officer	May 15	Sale	29.03	11,965	347,358	208,417	May 17 04:58 PM
Yeramian Patrick D	Chief Medical Officer	Apr 17	Option Exercise	0.99	49,579	49,058	257,996	Apr 19 07:45 PM
Yeramian Patrick D	Chief Medical Officer	Apr 17	Sale	30.54	49,579	1,513,942	208,417	Apr 19 07:45 PM
Morningside Venture Investment	10% Owner	Mar 29	Sale	30.45	29,048	884,512	6,997,302	Mar 31 04:05 PM
Morningside Venture Investment	10% Owner	Mar 28	Sale	30.37	100,000	3,037,000	7,026,350	Mar 29 04:05 PM
Morningside Venture Investment	10% Owner	Mar 27	Sale	30.50	60,964	1,859,561	7,126,350	Mar 29 04:05 PM
Morningside Venture Investment	10% Owner	Mar 21	Sale	31.91	63,448	2,024,494	7,187,314	Mar 23 04:05 PM
Firestone Karen	Director	Mar 16	Buy	31.99	1,000	31,990	1,000	Mar 20 08:22 PM
Cohen Joshua B	Co-Chief Executive Officer	Mar 16	Sale	31.86	100,000	3,186,336	2,792,617	Mar 20 08:21 PM
Klee Justin B.	Co-Chief Executive Officer	Mar 16	Sale	31.86	100,000	3,186,236	2,792,617	Mar 20 08:31 PM
Yeramian Patrick D	Chief Medical Officer	Mar 16	Sale	31.87	54,627	1,741,200	149,672	Mar 20 08:25 PM
MILNE GEORGE M JR	Director	Mar 16	Sale	31.89	35,000	1,116,072	862,021	Mar 20 08:25 PM
FRATES JAMES M	Chief Financial Officer	Mar 16	Sale	31.89	32,500	1,036,459	1,509	Mar 20 08:18 PM
Morningside Venture Investment	10% Owner	Mar 16	Sale	32.55	9,122	296,921	7,250,762	Mar 17 04:05 PM
Morningside Venture Investment	10% Owner	Mar 15	Sale	33.27	150,000	4,990,997	7,259,884	Mar 16 04:11 PM
Morningside Venture Investment	10% Owner	Mar 14	Sale	34.54	70,714	2,442,462	7,409,884	Mar 16 04:11 PM
Morningside Venture Investment	10% Owner	Mar 02	Sale	33.75	50,000	1,687,500	7,480,598	Mar 06 09:10 AM
Mazzariello Gina	Chief Legal Officer	Feb 24	Sale	34.49	3,586	123,672	37,414	Feb 28 04:42 PM
Morningside Venture Investment	10% Owner	Feb 23	Sale	35.57	50,000	1,778,267	7,580,598	Feb 24 04:13 PM
Morningside Venture Investment	10% Owner	Feb 22	Sale	36.00	50,000	1,799,836	7,630,598	Feb 24 04:13 PM
Morningside Venture Investment	10% Owner	Feb 22	Sale	34.73	50,000	1,736,352	7,530,598	Feb 28 04:06 PM
FRATES JAMES M	Chief Financial Officer	Dec 30	Option Exercise	6.88	5,000	34,400	36,667	Jan 04 09:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AMLX

Amylyx Pharmaceuticals Inc

Upgrade your FINVIZ experience